Clinical Characteristics and Treatment Results of Childhood Acute Lymphoblastic Leukemia in North Macedonia

1. SEER Cancer Statistics Review, 1975-2014. National Cancer Institute, Bethesda, MD 2017, Section 28.Search in Google Scholar

2. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16): 3206–14.10.1182/blood-2009-10-248146Search in Google Scholar

3. Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013; 14(3): 199–209.10.1016/S1470-2045(12)70600-9Search in Google Scholar

4. Pieters R, de Groot-Kruseman H, Van der Velden V, et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. Journal of Clinical Oncology 2016; 34(22): 2591–601.10.1200/JCO.2015.64.6364Search in Google Scholar

5. Domenech C, Suciu S, De Moerloose B, et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica. 2014 Jul; 99(7): 1220–7.10.3324/haematol.2014.103507Search in Google Scholar

6. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol 2012; 30, 1663–1669.10.1200/JCO.2011.37.8018Search in Google Scholar

7. Pui CH, Pei D, Coustan-Smith E, Jeha S, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015 Apr; 16(4): 465–74.10.1016/S1470-2045(15)70082-3Search in Google Scholar

8. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05–001): a randomised, open-label phase 3 trial. Lancet Oncol 2015; 16(16): 1677–90.10.1016/S1470-2045(15)00363-0Search in Google Scholar

9. Stary J, Zimmermann M, Campbell M, et al. Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002. J Clin Oncol. 2014; 32(3): 174–184.10.1200/JCO.2013.48.652224344215Search in Google Scholar

10. Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 354: 166–178, 2006.10.1056/NEJMra05260316407512Search in Google Scholar

11. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111: 4477–4489.10.1182/blood-2007-09-11292018285545Search in Google Scholar

12. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood. 2004; 104: 2690–2696.10.1182/blood-2004-04-1616Search in Google Scholar

13. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan; 14(1): 18–24.10.1200/JCO.1996.14.1.18Search in Google Scholar

14. Maloney KW, Shuster JJ, Murphy S, et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994. Leukemia 2000; 14: 2276.10.1038/sj.leu.2401965Search in Google Scholar

15. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429.10.1016/S1470-2045(10)70066-8Search in Google Scholar

16. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997; 80(9): 1717–26.10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-BSearch in Google Scholar

17. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia. 2000 Dec; 14(12): 2205–22.10.1038/sj.leu.2401973Search in Google Scholar

18. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998 Nov 28; 352(9142): 1731–8.10.1016/S0140-6736(98)04058-6Search in Google Scholar

19. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000; 96: 2691–2696.10.1182/blood.V96.8.2691Search in Google Scholar

20. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008; 111(12): 5477–5485.10.1182/blood-2008-01-132837Search in Google Scholar

21. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011; 118(8): 2077–84.10.1182/blood-2011-03-338707Search in Google Scholar

22. Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014; 15(8): 809–18.10.1016/S1470-2045(14)70243-8Search in Google Scholar

23. Republic of Macedonia. State Statistical Office. Census of population, households and dwellings in the Republic of Macedonia, 2002 - BooK XIII. Skopje, Republic of Macedonia: State Statistical Office; 2005.Search in Google Scholar

24. Jovanovska A, Martinova K, Kocheva S, et al. Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia. Open Access Maced J Med Sci. 2019 Sep 14; 7(17): 2818–2823.10.3889/oamjms.2019.752Search in Google Scholar

25. Silverman L.B., Gelber R.D., Dalton V.K., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97(5): 1211–1218.10.1182/blood.V97.5.1211Search in Google Scholar

26. Lim JY, Bhatia S, Robison LL, et al. Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia. Cancer. 2014 Apr 1; 120(7): 955–62.10.1002/cncr.28531Search in Google Scholar

27. Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019 Mar; 20(3): e142-e154.10.1016/S1470-2045(19)30031-2Search in Google Scholar

28. Hargrave DR, Hann II, Richards SM, et al. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J Haematol 2001; 112: 293–299.10.1046/j.1365-2141.2001.02543.x11167821Search in Google Scholar

29. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group Report. Leukemia. 2010 Feb; 24(2): 285–97.10.1038/leu.2009.262290613920016531Search in Google Scholar

30. Antillón FG, Blanco JG, Valverde PD, et al. The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results. Cancer. 2017 Feb 1; 123(3): 436–448.10.1002/cncr.3025727683100Search in Google Scholar

31. Aricò M, Valsecchi MG, Rizzari C, et al. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol. 2008 Jan 10; 26(2): 283–9.10.1200/JCO.2007.12.392718182669Search in Google Scholar

32. Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010 Feb; 24(2):265–84.10.1038/leu.2009.25720010625Search in Google Scholar

33. Lauten M, Möricke A, Beier R, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012 Jul; 97(7): 1048–56.10.3324/haematol.2011.047613339667722271901Search in Google Scholar

34. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report. Leukemia. 2010 Feb; 24(2): 285–97.10.1038/leu.2009.262290613920016531Search in Google Scholar